Status:
RECRUITING
Dapagliflozin and Endothelin Receptor Antagonist in Large Vessel Vasculitis (DERAIL-LVV)
Lead Sponsor:
University of Edinburgh
Conditions:
Large Vessel Vasculitis
Giant Cell Arteritis (GCA)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Large vessel vasculitis is a disease that causes damage to blood vessels. This damage to blood vessels can increase the risk of patients with LVV developing cardiovascular disease, including heart att...
Detailed Description
Large vessel vasculitis (LVV) is an autoimmune disease characterised by inflammatory damage to the blood vessels. Although symptoms initially are non-specific, complications such as vessel stenosis ca...
Eligibility Criteria
Inclusion
- A diagnosis of large vessel vasculitis that has been in remission for ≥ 6 months.
Exclusion
- Age \<18 years
- Active LVV
- Any organ transplant recipients
- A requirement for any medications that are contra-indicated whilst taking Bosentan
- Congestive cardiac failure
- Patients not medically fit to attend study visits
- Patients without mental capacity or willingness to provide informed consent
- History of multiple and/or severe (clinical judgement as determined by the Investigator) allergic reactions to drugs, including the study drug, or food
- Patients who are pregnant or breast feeding, or those who plan to become pregnant during the study
- Participation in another clinical trial for 28 days before or 90 days after the study period
Key Trial Info
Start Date :
March 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06887062
Start Date
March 21 2025
End Date
July 1 2027
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Edinburgh
Edinburgh, United Kingdom, EH16 4TJ